Anlon Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026, considered at the Board Meeting held on 29th May, 2026.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anlon Healthcare Limited reported strong audited financial results for FY2026 (ended March 31, 2026). Standalone revenue from operations grew 46.7% to Rs. 17,649.87 Lakhs from Rs. 12,028.66 Lakhs in FY2025. Standalone profit after tax increased 35.5% to Rs. 2,780.82 Lakhs from Rs. 2,051.79 Lakhs. The company, which listed on NSE and BSE in September 2025, manufactures Active Pharmaceutical Ingredients (APIs) and drug intermediates. On a consolidated basis (including subsidiaries Bizotic Lifescience and Apiqo Organics), revenue rose to Rs. 17,196.56 Lakhs and consolidated PAT was Rs. 2,908.81 Lakhs. The statutory auditor RVD & Co issued an un-modified (clean) opinion on both standalone and consolidated results, confirming no material misstatements.
The company demonstrated robust double-digit revenue and profit growth in its first full financial year post-IPO, which is positive for shareholders. The clean audit opinion removes any immediate concerns about financial reporting quality.